ArticlePloS one2020
Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.PloS one · 2025Pooled it
- Pooled it
- Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.PharmacoEconomics · 2026Article
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA.PharmacoEconomics · 2025Article
- Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.BMC public health · 2025Article
- Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare.Infectious diseases and therapy · 2023Article
- Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the future.The Lancet regional health. Western Pacific · 2022Article
- Etiological and epidemiological features of acute meningitis or encephalitis in China: a nationwide active surveillance study.The Lancet regional health. Western Pacific · 2022Article
- Characterization of Meningitis and Meningoencephalitis in the Israeli Defense Forces From 2004 to 2015: A Population-Based Study.Frontiers in neurology · 2022Article
- Meningococcal disease and vaccination in college students.Human vaccines & immunotherapeutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUniversity students are at significantly higher risk of serogroup B meningococcal (MenB) infection, which can result in debilitating sequelae and excessive healthcare usage. This study aimed to elucidate the impact of universal pre-enrollment vaccination on MenB outbreak probability and the cost-effectiveness in outbreak-only scenarios.
methodsWe developed an infectious disease transmission model to determine the number of outbreaks averted under universal vaccination and a Markov model to simulate the costs accrued and QALYs lost associated with infection. The analysis was done on a hypothetical population of 40,000 college students over a four-year time frame. We used the outputs of these two models to calculate the incremental cost-effectiveness ratio (ICER) of universal MenB vaccination from a societal perspective.
resultsWe find that the vaccination strategy was estimated to reduce MenB incidence by 63% and outbreak frequency rate by 90%. Under base case assumptions, the ICER of universal vaccination was $748,129 per QALY and in outbreak-only scenarios, it was cost-saving.
conclusionsUniversal vaccination is not cost-effective at the current low MenB incidence levels and vaccine price in the U.S., but it is cost-saving if outbreak is imminent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.